M. McDonnell (Oranmore (Co Galway), Ireland), J. Vestbo (Manchester (Greater Manchester), United Kingdom)
Late Breaking Abstract - Effect of inhaled corticosteroids on exacerbation of asthma–COPD overlap according to different diagnostic criteria
C. Rhee (Seoul, Republic of Korea), Y. Jo (Seoul, Republic of Korea), Y. Hwang (Ahnyang, Republic of Korea), K. Yoo (Seoul, Republic of Korea), H. Yoon (Seoul, Republic of Korea)
|   |
Late Breaking Abstract - High blood neutrophils are associated with increased exacerbations and mortality in Chronic Obstructive Pulmonary Disease
M. Lonergan (Dundee, United Kingdom), A. Dicker (Dundee, United Kingdom), M. Crichton (Dundee, United Kingdom), C. Fong (Dundee, United Kingdom), H. Keir (Dundee, United Kingdom), A. Cassidy (Dundee, United Kingdom), M. Van Dyke (Collegeville, United States of America), H. Mullerova (Uxbridge, United Kingdom), B. Miller (Collegeville, United States of America), R. Tal-Singer (Collegeville, United States of America), J. Chalmers (Dundee, United Kingdom)
| |
Evaluation of the association between eosinophil variability and effects of inhaled corticosteroids in COPD patients using propensity score matching
J. YOON (Seoul, Republic of Korea), J. Lee (Seoul, Republic of Korea), E. Heo (Seoul, Republic of Korea), H. Chung (Seoul, Republic of Korea), C. Lee (Seoul, Republic of Korea), H. Yoon (Seongnam, Republic of Korea), Y. Hwang (Anyang, Republic of Korea), C. Rhee (Seoul, Republic of Korea), K. Yoo (Seoul, Republic of Korea), D. Kim (Seoul, Republic of Korea)
| |
Blood eosinophil counts, withdrawal of inhaled corticosteroids and risk of COPD exacerbations and mortality in the Clinical Practice Research Datalink (CPRD)
O. Oshagbemi (Maastricht, Netherlands), F. Franssen (Maastricht, Netherlands), E. Wouters (Maastricht, Netherlands), A. Maitland-Van Der Zee (Amsterdam, Netherlands), J. Driessen (Maastricht, Netherlands), A. De Boer (Maastricht, Netherlands), F. Devries (Maastricht, Netherlands), D. Braeken (Maastricht, Netherlands)
| |
Improvements in Clinical Outcomes Associated with Reduction in Hyperinflation with Zephyr Valves
F. Sciurba (Pittsburgh, United States of America), R. Sue (Phoenix, United States of America), H. Rivas-Perez (Louisville, United States of America), B. Morrissey (Sacramento, United States of America), H. Goulart De Oliveira (Porto Alegre, Brazil), M. Wahidi (Durham, United States of America), P. F G Cardoso (Sao Paulo, Brazil), N. Pastis Jr (Charleston, United States of America), M. Dransfield (Birmingham, United States of America), P. Shah (London, United Kingdom), S. Radhakrishnan (Redwwod City, United States of America), N. Shargill (Redwwod City, United States of America), G. Criner (Philadelphia, United States of America), D. Slebos (Groningen, Netherlands)
| |
Pneumonia risk with budesonide-containing therapies in COPD: pooled analysis of three Phase III studies
G. Ferguson (Farmington Hills, United States of America), K. Rabe (Grosshansdorf, Germany), N. Hanania (Houston, United States of America), S. Ballal (Morristown, United States of America), J. Nyberg (Morristown, United States of America), P. Darken (Morristown, United States of America), K. Deangelis (Durham, United States of America), P. Dorinsky (Durham, United States of America)
| |
Relative bioavailability of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) administered with and without a spacer in healthy adults
P. Dorinsky (Durham, United States of America), P. Depetrillo (Baltimore, United States of America), K. Deangelis (Durham, United States of America), R. Trivedi (Durham, United States of America), M. Mo (Morristown, United States of America), S. Ballal (Morristown, United States of America), M. Gillen (Gaithersburg, United States of America)
| |
RNAscope in situ hybridization allows spatial estimation of free drug exposure through quantification of drug induced gene expression
G. Skogberg (Gothenburg, Sweden), S. Jackson (Gothenburg, Sweden), B. Fihn (Gothenburg, Sweden), U. Tehler (Gothenburg, Sweden), J. Karlsson (Gothenburg, Sweden), M. Hühn (Gothenburg, Sweden), M. Fridén (Gothenburg, Sweden)
| |
Bidimensional comparative analysis of LABA/LAMA FDCs in COPD
P. Rogliani (Rome, Italy), J. Ora (Rome, Italy), M. Matera (Naples, Italy), M. Cazzola (Rome, Italy), L. Calzetta (Rome, Italy)
| |
Novel lung function tests can improve phenotyping and differential therapy in COPD
F. Trinkmann (Mannheim, Germany), J. Gawlitza (Mannheim, Germany), J. Schäfer (Mannheim, Germany), M. Schroeter (Mannheim, Germany), J. Drayß (Mannheim, Germany), J. Michels (Mannheim, Germany), M. Borggrefe (Mannheim, Germany), I. Akin (Mannheim, Germany), J. Saur (Mannheim, Germany)
| |
Use of steroid in COPD patients and the risk of femur neck fracture; nested case-control study
H. Kim (Seoul, Republic of Korea), I. Park (Seoul, Republic of Korea), B. Choi (Seoul, Republic of Korea), J. Kim (Seoul, Republic of Korea), J. Shin (Seoul, Republic of Korea), J. Choi (Seoul, Republic of Korea), J. Jung (Seoul, Republic of Korea), S. Yoon (Seoul, Republic of Korea), G. Lee (Seoul, Republic of Korea), H. Shin (Seoul, Republic of Korea)
| |
Effect of indacaterol/glycopyrronium on ventilation/perfusion match and ventilation dynamics in hyperinflated COPD patients: The CLAIM study
A. Voskrebenzev (Hannover, Germany), T. Kaireit (Hannover, Germany), F. Klimeš (Hannover, Germany), G. Pöhler (Hannover, Germany), L. Behrendt (Hannover, Germany), K. Berschneider (Nuremberg, Germany), F. Wacker (Hannover, Germany), T. Welte (Hannover, Germany), J. Hohlfeld (Hannover, Germany), J. Vogel-Claussen (Hannover, Germany)
| |
Benefits of tiotropium/olodaterol compared with tiotropium in patients with COPD receiving only LAMA at baseline: pooled analysis of 4 clinical trials
R. Buhl (Mainz, Germany), D. Singh (Manchester, United Kingdom), A. De La Hoz (Ingelheim am Rhein, Germany), F. Voß (Ingelheim am Rhein, Germany), G. Ferguson (Farmington Hills, United States of America)
| |
Comparison of outcomes in augmentation naïve and augmented patients with alpha-1 antitrypsin deficiency related lung disease.
P. Ellis (Birmingham, United Kingdom), K. Holm (Denver, United States of America), R. Choate (Lexington, United States of America), D. Mannino (Lexington, United States of America), R. Stockley (Birmingham, United Kingdom), R. Sandhaus (Denver, United States of America), A. Turner (Birmingham, United Kingdom)
| |
Effects of combined tiotropium/olodaterol on dynamic lung hyperinflation evaluated by the incremental hyperventilation method
S. Kawachi (Matsumoto, Japan), K. Fujimoto (Matsumoto, Japan)
| |
Characteristics and treatment patterns of newly diagnosed COPD patients in Canada
N. Dhalwani (London, United Kingdom), C. Cabrera (Mölndal, Sweden), A. Booth (London, United Kingdom), R. Petrella (London, Canada), D. Lambrelli (London, United Kingdom)
| |
Targeted Retreatment of Incompletely Resolved COPD Exacerbations With Ciprofloxacin
A. Ritchie (London, United Kingdom), S. Brill (London, United Kingdom), B. Vlies (Liverpool, United Kingdom), L. Finney (London, United Kingdom), J. Allinson (London, United Kingdom), L. Alves-Moreira (London, United Kingdom), P. Walker (Liverpool, United Kingdom), E. Baker (London, United Kingdom), S. Elkin (London, United Kingdom), P. Mallia (London, United Kingdom), G. Donaldson (London, United Kingdom), P. Calverley (Liverpool, United Kingdom), J. Wedzicha (London, United Kingdom)
| |
Significance of reversibility in Lower Limit of Normal defined obstruction – The PneumoLaus study
B. Touilloux (Lausanne, Switzerland), A. Lenoir (Lausanne, Switzerland), J. Fitting (Lausanne, Switzerland), P. Vollenweider (Lausanne, Switzerland), L. Nicod (Lausanne, Switzerland)
| |